Drug-target Binding Research Articles

MREDTA: A BERT and transformer-based molecular representation encoder for predicting drug-target binding affinity.

Drug-target binding affinity (DTA) prediction is vital for drug repositioning. The accuracy and generalizability of DTA models remain a major challenge. Here, we develop a model composed of BERT-Trans Block, Multi-Trans Block, and DTI Learning modules, referred to as Molecular Representation Encoder-based DTA prediction (MREDTA). MREDTA has three advantages: (1) extraction of both local and global molecular features simultaneously through skip connections; (2) improved sensitivity to molecular structures through the Multi-Trans Block; (3) enhanced generalizability through the introduction of BERT. Compared with 12 advanced models, benchmark testing of KIBA and Davis datasets demonstrated optimal performance of MREDTA. In case study, we applied MREDTA to 2034 FDA-approved drugs for treating non-small-cell lung cancer (NSCLC), all of which act on mutant EGFRT790M protein. The corresponding molecular docking results demonstrated the robustness of MREDTA.

TC-DTA: Predicting Drug-Target Binding Affinity With Transformer and Convolutional Neural Networks.

Bioinformatics is a rapidly evolving field that applies computational methods to analyze and interpret biological data. A key task in bioinformatics is identifying novel drug-target interactions (DTIs), which plays a crucial role in drug discovery. Most computational approaches treat DTI prediction as a binary classification problem, determining whether drug-target pairs interact. However, with the growing availability of drug-target binding affinity data, this binary task can be reframed as a regression problem focused on drug-target affinity (DTA). DTA quantifies the strength of drug-target binding, offering more detailed insights than DTI and serving as a valuable tool for virtual screening in drug discovery. Accurately predicting compound interactions with targets can accelerate the drug development process. In this study, we introduce a deep learning model named TC-DTA for DTA prediction, leveraging convolutional neural networks (CNN) and the encoder module of the transformer architecture. We begin by extracting raw drug SMILES strings and protein amino acid sequences from the dataset, which are then represented using various encoding methods. Subsequently, we employ CNN and the transformer's encoder module to extract features from the drug SMILES strings and protein sequences, respectively. Finally, the feature information is concatenated and input into a multi-layer perceptron to predict binding affinity scores. We evaluated our model on two benchmark DTA datasets, Davis and KIBA, comparing it with methods such as KronRLS, SimBoost, and DeepDTA. Our model, TC-DTA, outperformed these baseline methods based on evaluation metrics like Mean Squared Error (MSE), Concordance Index (CI), and Regression towards the Mean Index ( rm2 ). These results highlight the effectiveness of the Transformer's encoder and CNN in extracting meaningful representations from sequences, thereby enhancing DTA prediction accuracy. This deep learning model can accelerate drug discovery by identifying drug candidates with high binding affinity to specific targets. Compared to traditional methods, machine learning technology offers a more effective and efficient approach to drug discovery.

PocketDTA: an advanced multimodal architecture for enhanced prediction of drug-target affinity from 3D structural data of target binding pockets.

Accurately predicting the drug-target binding affinity (DTA) is crucial to drug discovery and repurposing. Although deep learning has been widely used in this field, it still faces challenges with insufficient generalization performance, inadequate use of 3D information, and poor interpretability. To alleviate these problems, we developed the PocketDTA model. This model enhances the generalization performance by pre-trained models ESM-2 and GraphMVP. It ingeniously handles the first 3 (top-3) target binding pockets and drug 3D information through customized GVP-GNN Layers and GraphMVP-Decoder. In addition, it uses a bilinear attention network to enhance interpretability. Comparative analysis with state-of-the-art (SOTA) methods on the optimized Davis and KIBA datasets reveals that the PocketDTA model exhibits significant performance advantages. Further, ablation studies confirm the effectiveness of the model components, whereas cold-start experiments illustrate its robust generalization capabilities. In particular, the PocketDTA model has shown significant advantages in identifying key drug functional groups and amino acid residues via molecular docking and literature validation, highlighting its strong potential for interpretability. Code and data are available at: https://github.com/zhaolongNCU/PocketDTA.

DTA Atlas: A massive-scale drug repurposing database

The drug development process is costly and time-consuming. Repurposing existing approved drugs, an efficient and cost-effective strategy, involves assessing numerous drug-protein pairs to uncover new interactions. While modern in silico methods enhance scalability, an open database for projected drug-target interactions across the entire human proteome is still lacking. In this work, we introduce an open database of predicted drug-target interactions, termed DTA Atlas, covering the entire human proteome as well as a wide range of marketed drugs, resulting in over 220 million drug-target pairs. The database integrates 4 billion affinity predictions from advanced deep neural networks and offers a user-friendly web interface, enabling users to explore drug-target affinity predictions for the human proteome. To the best of our knowledge, DTA Atlas represents the first comprehensive collection of drug-target binding strength predictions. It is open-source and can serve as an important resource for drug development, drug repurposing, toxicity studies and more.

Structure-inclusive similarity based directed GNN: a method that can control information flow to predict drug-target binding affinity.

Exploring the association between drugs and targets is essential for drug discovery and repurposing. Comparing with the traditional methods that regard the exploration as a binary classification task, predicting the drug-target binding affinity can provide more specific information. Many studies work based on the assumption that similar drugs may interact with the same target. These methods constructed a symmetric graph according to the undirected drug similarity or target similarity. Although these similarities can measure the difference between two molecules, it is unable to analyze the inclusion relationship of their substructure. For example, if drug A contains all the substructures of drug B, then in the message-passing mechanism of the graph neural network, drug A should acquire all the properties of drug B, while drug B should only obtain some of the properties of A. To this end, we proposed a structure-inclusive similarity (SIS) which measures the similarity of two drugs by considering the inclusion relationship of their substructures. Based on SIS, we constructed a drug graph and a target graph, respectively, and predicted the binding affinities between drugs and targets by a graph convolutional network-based model. Experimental results show that considering the inclusion relationship of the substructure of two molecules can effectively improve the accuracy of the prediction model. The performance of our SIS-based prediction method outperforms several state-of-the-art methods for drug-target binding affinity prediction. The case studies demonstrate that our model is a practical tool to predict the binding affinity between drugs and targets. Source codes and data are available at https://github.com/HuangStomach/SISDTA.

SSR-DTA: Substructure-aware multi-layer graph neural networks for drug–target binding affinity prediction

Accurate prediction of drug–target binding affinity (DTA) is essential in the field of drug discovery. Recently, scientists have been attempting to utilize artificial intelligence prediction to screen out a significant number of ineffective compounds, thereby mitigating labor and financial losses. While graph neural networks (GNNs) have been applied to DTA, existing GNNs have limitations in effectively extracting substructural features across various sizes. Functional groups play a crucial role in modulating molecular properties, but existing GNNs struggle with feature extraction from certain motifs due to scale mismatches. Additionally, sequence-based models for target proteins lack the integration of structural information. To address these limitations, we present SSR-DTA, a multi-layer graph network capable of adapting to diverse structural sizes, which can extract richer biological features, thereby improving the robustness and accuracy of predictions. Multi-layer GNNs enable the capture of molecular motifs across different scales, ranging from atomic to macrocyclic motifs. Furthermore, we introduce BiGNN to simultaneously learn sequence and structural information. Sequence information corresponds to the primary structure of proteins, while graph information represents the tertiary structure. BiGNN assimilates richer information compared to sequence-based methods while mitigating the impact of errors from predicted structures, resulting in more accurate predictions. Through rigorous experimental evaluations conducted on four benchmark datasets, we demonstrate the superiority of SSR-DTA over state-of-the-art models. Particularly, in comparison to state-of-the-art models, SSR-DTA demonstrates an impressive 20% reduction in mean squared error on the Davis dataset and a 5% reduction on the KIBA dataset, underscoring its potential as a valuable tool for advancing DTA prediction.

Enhancing Drug-Target Binding Affinity Prediction through Deep Learning and Protein Secondary Structure Integration

Background: Conventional approaches to drug discovery are often characterized by lengthy and costly processes. To expedite the discovery of new drugs, the integration of artificial intelligence (AI) in predicting drug-target binding affinity (DTA) has emerged as a crucial approach. Despite the proliferation of deep learning methods for DTA prediction, many of these methods primarily concentrate on the amino acid sequence of proteins. Yet, the interactions between drug compounds and targets occur within distinct segments within the protein structures, whereas the primary sequence primarily captures global protein features. Consequently, it falls short of fully elucidating the intricate relationship between drugs and their respective targets. Objective: This study aims to employ advanced deep-learning techniques to forecast DTA while incorporating information about the secondary structure of proteins. Methods: In our research, both the primary sequence of protein and the secondary structure of protein were leveraged for protein representation. While the primary sequence played the role of the overarching feature, the secondary structure was employed as the localized feature. Convolutional neural networks and graph neural networks were utilized to independently model the intricate features of target proteins and drug compounds. This approach enhanced our ability to capture drugtarget interactions more effectively Results: We have introduced a novel method for predicting DTA. In comparison to DeepDTA, our approach demonstrates significant enhancements, achieving a 3.9% increase in the Concordance Index (CI) and a remarkable 34% reduction in Mean Squared Error (MSE) when evaluated on the KIBA dataset. Conclusion: In conclusion, our results unequivocally demonstrate that augmenting DTA prediction with the inclusion of the protein's secondary structure as a localized feature yields significantly improved accuracy compared to relying solely on the primary structure.

MolMVC: Enhancing molecular representations for drug-related tasks through multi-view contrastive learning.

Effective molecular representation is critical in drug development. The complex nature of molecules demands comprehensive multi-view representations, considering 1D, 2D, and 3D aspects, to capture diverse perspectives. Obtaining representations that encompass these varied structures is crucial for a holistic understanding of molecules in drug-related contexts. In this study, we introduce an innovative multi-view contrastive learning framework for molecular representation, denoted as MolMVC. Initially, we use a Transformer encoder to capture 1D sequence information and a Graph Transformer to encode the intricate 2D and 3D structural details of molecules. Our approach incorporates a novel attention-guided augmentation scheme, leveraging prior knowledge to create positive samples tailored to different molecular data views. To align multi-view molecular positive samples effectively in latent space, we introduce an adaptive multi-view contrastive loss (AMCLoss). In particular, we calculate AMCLoss at various levels within the model to effectively capture the hierarchical nature of the molecular information. Eventually, we pre-train the encoders via minimizing AMCLoss to obtain the molecular representation, which can be used for various down-stream tasks. In our experiments, we evaluate the performance of our MolMVC on multiple tasks, including molecular property prediction (MPP), drug-target binding affinity (DTA) prediction and cancer drug response (CDR) prediction. The results demonstrate that the molecular representation learned by our MolMVC can enhance the predictive accuracy on these tasks and also reduce the computational costs. Furthermore, we showcase MolMVC's efficacy in drug repositioning across a spectrum of drug-related applications. The code and pre-trained model are publicly available at https://github.com/Hhhzj-7/MolMVC.

Drug-Target Binding Affinity Prediction in a Continuous Latent Space Using Variational Autoencoders.

Accurate prediction of Drug-Target binding Affinity (DTA) is a daunting yet pivotal task in the sphere of drug discovery. Over the years, a plethora of deep learning-based DTA models have emerged, rendering promising results in predicting the binding affinities between drugs and their target proteins. However, in contrast to the conventional approach of modeling binding affinity in vector spaces, we propose a more nuanced modeling process in a continuous space to account for the diversity of input samples. Initially, the drug is encoded using the Simplified Molecular Input Line Entry System (SMILES), while the target sequences are characterized via a pretrained language model. Subsequently, highly correlative information is extracted utilizing residual gated convolutional neural networks. In a departure from existing deep learning-based models, our model learns the hidden representations of the drugs and targets jointly. Instead of employing two vectors, our hidden representations consist of two Gaussian distributions. To validate the effectiveness of our proposal, we conducted evaluations on commonly utilized benchmark datasets. The experimental outcomes corroborated that our method surpasses the state-of-the-art vectorial representation methods in terms of performance. This approach, therefore, offers potential enhancements in the precision of DTA predictions, potentially contributing to more efficient drug discovery processes.

Optimized differential evolution and hybrid deep learning for superior drug-target binding affinity prediction

Investigating Drug-Target Interactions (DTI) is crucial for drug repositioning and discovery tasks. However, discovering DTIs through experimental approaches is time-consuming and requires substantial financial resources. To address these challenges, machine learning-based methodologies have been adopted to reduce costs and save time. Unfortunately, the effectiveness of these methods has been limited due to the binary classification approach and the lack of empirically validated negative samples. The availability of abundant DTI datasets and protein structure data has enabled the development of new approaches, such as redefining the DTI problem as a regression task. Given this context, we propose an innovative deep-learning approach to predict binding affinities between drugs and targets. Our model, named the Convolution Self-Attention Network with Attention-based Bidirectional Long Short-Term Memory Network (CSAN-BiLSTM-Att), integrates convolutional neural network (CNN) blocks with self-attention mechanisms to create an attention-based bidirectional long short-term memory (BiLSTM) model, followed by fully connected layers. Due to the model's complexity, proper hyperparameter tuning is essential. To optimize this, we employ the Differential Evolution (DE) technique to select the most suitable hyperparameters. Experimental results demonstrate that the DE-based CSAN-BiLSTM-Att model outperforms previous approaches. Specifically, the model achieved a concordance index of 0.898 and a mean square error of 0.228 on the DAVIS dataset, and a concordance value of 0.971 with a mean square error of 0.014 on the KIBA dataset.

MMD-DTA: A multi-modal deep learning framework for drug-target binding affinity and binding region prediction.

The prediction of drug-target affinity (DTA) plays a crucial role in drug development and the identification of potential drug targets. In recent years, computer-assisted DTA prediction has emerged as a significant approach in this field. In this study, we propose a multi-modal deep learning framework called MMD-DTA for predicting drug-target binding affinity and binding regions. The model can predict DTA while simultaneously learning the binding regions of drug-target interactions through unsupervised learning. To achieve this, MMD-DTA first uses graph neural networks and target structural feature extraction network to extract multi-modal information from the sequences and structures of drugs and targets. It then utilizes the feature interaction and fusion modules to generate interaction descriptors for predicting DTA and interaction strength for binding region prediction. Our experimental results demonstrate that MMD-DTA outperforms existing models based on key evaluation metrics. Furthermore, external validation results indicate that MMD-DTA enhances the generalization capability of the model by integrating sequence and structural information of drugs and targets. The model trained on the benchmark dataset can effectively generalize to independent virtual screening tasks. The visualization of drug-target binding region prediction showcases the interpretability of MMD-DTA, providing valuable insights into the functional regions of drug molecules that interact with proteins.

Differences in Mitochondrial Cytochrome b Binding Mediate Selectivity of Bifenazate toward Phytophagous and Predatory Mites.

Bifenazate, a potent acaricide that targets mitochondrial complex III, exhibits selective toxicity (>280-fold) toward phytophagous mites versus predatory mites. Here, a systematic study was conducted to clarify the selective mechanism. Nontarget factors were excluded through epidermal penetration tests and assessment of detoxification enzymes' activities. Quantification of IC50 values, ATP content, and reactive oxygen species (ROS) levels revealed that differences in drug-target binding determine the toxicity selectivity. Structural modeling and molecular docking revealed that variations in key amino acid sites within the cytochrome b (cytb) target might regulate this selectivity, which was validated through a microscale thermophoresis assay. Significant disparities were observed in the binding affinity between bifenazate and recombinant cytb proteins derived from phytophagous mites and predatory mites. Mutating isoleucine 139 to leucine notably reduced the binding affinity of bifenazate to cytb. Insights into bifenazate selectivity between phytophagous and predatory mites inform a basis for developing compounds that target cytochrome b.

GraphCL-DTA: A Graph Contrastive Learning With Molecular Semantics for Drug-Target Binding Affinity Prediction.

Drug-target binding affinity prediction plays an important role in the early stages of drug discovery, which can infer the strength of interactions between new drugs and new targets. However, the performance of previous computational models is limited by the following drawbacks. The learning of drug representation relies only on supervised data without considering the information in the molecular graph itself. Moreover, most previous studies tended to design complicated representation learning modules, while uniformity used to measure representation quality is ignored. In this study, we propose GraphCL-DTA, a graph contrastive learning with molecular semantics for drug-target binding affinity prediction. This graph contrastive learning framework replaces the dropout-based data augmentation strategy by performing data augmentation in the embedding space, thereby better preserving the semantic information of the molecular graph. A more essential and effective drug representation can be learned through this graph contrastive framework without additional supervised data. Next, we design a new loss function that can be directly used to adjust the uniformity of drug and target representations. By directly optimizing the uniformity of representations, the representation quality of drugs and targets can be improved. The effectiveness of the above innovative elements is verified on two real datasets, KIBA and Davis. Compared with the GraphDTA model, the relative improvement of the GraphCL-DTA model on the two datasets is 2.7% and 4.5%. The graph contrastive learning framework and uniformity function in the GraphCL-DTA model can be embedded into other computational models as independent modules to improve their generalization capability.

Novel energy optimizer, meldonium, rapidly restores acute hypobaric hypoxia-induced brain injury by targeting phosphoglycerate kinase 1

BackgroundAcute hypobaric hypoxia-induced brain injury has been a challenge in the health management of mountaineers; therefore, new neuroprotective agents are urgently required. Meldonium, a well-known cardioprotective drug, has been reported to have neuroprotective effects. However, the relevant mechanisms have not been elucidated. We hypothesized that meldonium may play a potentially novel role in hypobaric hypoxia cerebral injury.MethodsWe initially evaluated the neuroprotection efficacy of meldonium against acute hypoxia in mice and primary hippocampal neurons. The potential molecular targets of meldonium were screened using drug-target binding Huprot™ microarray chip and mass spectrometry analyses after which they were validated with surface plasmon resonance (SPR), molecular docking, and pull-down assay. The functional effects of such binding were explored through gene knockdown and overexpression.ResultsThe study clearly shows that pretreatment with meldonium rapidly attenuates neuronal pathological damage, cerebral blood flow changes, and mitochondrial damage and its cascade response to oxidative stress injury, thereby improving survival rates in mice brain and primary hippocampal neurons, revealing the remarkable pharmacological efficacy of meldonium in acute high-altitude brain injury. On the one hand, we confirmed that meldonium directly interacts with phosphoglycerate kinase 1 (PGK1) to promote its activity, which improved glycolysis and pyruvate metabolism to promote ATP production. On the other hand, meldonium also ameliorates mitochondrial damage by PGK1 translocating to mitochondria under acute hypoxia to regulate the activity of TNF receptor-associated protein 1 (TRAP1) molecular chaperones.ConclusionThese results further explain the mechanism of meldonium as an energy optimizer and provide a strategy for preventing acute hypobaric hypoxia brain injury at high altitudes.

Drug–target binding affinity prediction model based on multi-scale diffusion and interactive learning

Drug–target interactions (DTIs) play a key role in drug discovery and development as they are critical in understanding the complex mechanisms of underlying drugs and their corresponding targets. Unfortunately, some studies do not fully recognize the significant contribution of graph structure to drug feature extraction, thereby neglecting the extraction of local and global structures inherent in molecular graphs. Furthermore, most existing drug–target binding affinity (DTA) prediction models ignore or simplify complex interaction mechanisms, thus compromising the predictive power of the models. Therefore, this paper proposes a novel DTA prediction model utilizing multi-scale diffusion and interactive learning (MDCT-DTA). To address the limitations of current methods, the multi-scale graph diffusion convolution (MGDC) module is introduced, which can effectively capture the complex interactions between drug molecular graph nodes. Furthermore, a CNN-Transformer Network (CTN) block is proposed to capture the interactions and interdependencies between different amino acids, thereby enhancing the representation and learning capabilities of the model. In addition, a local inter-layer information interaction structure is designed to specifically explore the relationship between drug features and protein features, so as to improve the representativeness and robustness of the model’s structural features. The performance of the proposed model was evaluated using four publicly available benchmark datasets, Davis, KIBA, BindingDB, and Metz. The experimental results confirm that the proposed model can more accurately predict the binding affinity between a drug and its targets. They also provide a new perspective for the prediction task of DTA and contribute to the overall development and improvement of DTA prediction models.

Enhancing generalizability and performance in drug-target interaction identification by integrating pharmacophore and pre-trained models.

In drug discovery, it is crucial to assess the drug-target binding affinity (DTA). Although molecular docking is widely used, computational efficiency limits its application in large-scale virtual screening. Deep learning-based methods learn virtual scoring functions from labeled datasets and can quickly predict affinity. However, there are three limitations. First, existing methods only consider the atom-bond graph or one-dimensional sequence representations of compounds, ignoring the information about functional groups (pharmacophores) with specific biological activities. Second, relying on limited labeled datasets fails to learn comprehensive embedding representations of compounds and proteins, resulting in poor generalization performance in complex scenarios. Third, existing feature fusion methods cannot adequately capture contextual interaction information. Therefore, we propose a novel DTA prediction method named HeteroDTA. Specifically, a multi-view compound feature extraction module is constructed to model the atom-bond graph and pharmacophore graph. The residue concat graph and protein sequence are also utilized to model protein structure and function. Moreover, to enhance the generalization capability and reduce the dependence on task-specific labeled data, pre-trained models are utilized to initialize the atomic features of the compounds and the embedding representations of the protein sequence. A context-aware nonlinear feature fusion method is also proposed to learn interaction patterns between compounds and proteins. Experimental results on public benchmark datasets show that HeteroDTA significantly outperforms existing methods. In addition, HeteroDTA shows excellent generalization performance in cold-start experiments and superiority in the representation learning ability of drug-target pairs. Finally, the effectiveness of HeteroDTA is demonstrated in a real-world drug discovery study. The source code and data are available at https://github.com/daydayupzzl/HeteroDTA.

ImageDTA: A Simple Model for Drug-Target Binding Affinity Prediction.

Predicting the drug-target binding affinity (DTA) is crucial in drug discovery, and an increasing number of researchers are using artificial intelligence techniques to make such predictions. Many effective deep neural network prediction models have been proposed. However, current methods need improvement in accuracy, complexity, and efficiency. In this study, we propose a method based on a multiscale 2-dimensional convolutional neural network (CNN), namely ImageDTA. Many studies have shown that CNN achieves good learning effects with limited data. Therefore, we take a unique perspective by treating the word vector encoded with a simplified molecular input line entry system (SMILES) string as an "image" and processing it like handling images, fully leveraging the efficient processing capabilities of CNN for image data. Furthermore, we show that ImageDTA has higher training and inference efficiency than pretrained large models and outperforms attention-based graph neural network models in accuracy and interpretability. We also use visualization techniques to select appropriate convolutional kernel sizes, thereby increasing the network's interpretability.

MDF-DTA: A Multi-Dimensional Fusion Approach for Drug-Target Binding Affinity Prediction.

Drug-target affinity (DTA) prediction is an important task in the early stages of drug discovery. Traditional biological approaches are time-consuming, effort-consuming, and resource-consuming due to the large size of genomic and chemical spaces. Computational approaches using machine learning have emerged to narrow down the drug candidate search space. However, most of these prediction models focus on single feature encoding of drugs and targets, ignoring the importance of integrating different dimensions of these features. We propose a deep learning-based approach called Multi-Dimensional Fusion for Drug Target Affinity Prediction (MDF-DTA) incorporating different dimensional features. Our model fuses 1D, 2D, and 3D representations obtained from different pretrained models for both drugs and targets. We evaluated MDF-DTA on two standard benchmark data sets: DAVIS and KIBA. Experimental results show that MDF-DTA outperforms many state-of-the-art techniques in the DTA task across both data sets. Through ablation studies and performance evaluation metrics, we evaluate the importance of individual representations and the impact of each representation on MDF-DTA.

Prediction of drug–target binding affinity based on multi-scale feature fusion

Accurate prediction of drug–target binding affinity (DTA) plays a pivotal role in drug discovery and repositioning. Although deep learning methods are widely used in DTA prediction, two significant challenges persist: (i) how to effectively represent the complex structural information of proteins and drugs; (ii) how to precisely model the mutual interactions between protein binding sites and key drug substructures. To address these challenges, we propose a MSFFDTA (Multi-scale feature fusion for predicting drug target affinity) model, in which multi-scale encoders effectively capture multi-level structural information of drugs and proteins are designed. And then a Selective Cross Attention (SCA) mechanism is developed to filter out the trivial interactions between drug–protein substructure pairs and retain the important ones, which will make the proposed model better focusing on these key interactions and offering insights into their underlying mechanism. Experimental results on two benchmark datasets demonstrate that MSFFDTA is superior to several state-of-the-art methods across almost all comparison metrics. Finally, we provide the ablation and case studies with visualizations to verify the effectiveness and the interpretability of MSFFDTA. The source code is freely available at https://github.com/whitehat32/MSFF-DTA/.

Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction.

The attrition rate of drugs in clinical trials is generally quite high, with estimates suggesting that approximately 90% of drugs fail to make it through the process. The identification of unexpected toxicity issues during preclinical stages is a significant factor contributing to this high rate of failure. These issues can have a major impact on the success of a drug and must be carefully considered throughout the development process. These late-stage rejections or withdrawals of drug candidates significantly increase the costs associated with drug development, particularly when toxicity is detected during clinical trials or after market release. Understanding drug-biological target interactions is essential for evaluating compound toxicity and safety, as well as predicting therapeutic effects and potential off-target effects that could lead to toxicity. This will enable scientists to predict and assess the safety profiles of drug candidates more accurately. Evaluation of toxicity and safety is a critical aspect of drug development, and biomolecules, particularly proteins, play vital roles in complex biological networks and often serve as targets for various chemicals. Therefore, a better understanding of these interactions is crucial for the advancement of drug development. The development of computational methods for evaluating protein-ligand interactions and predicting toxicity is emerging as a promising approach that adheres to the 3Rs principles (replace, reduce, and refine) and has garnered significant attention in recent years. In this review, we present a thorough examination of the latest breakthroughs in drug toxicity prediction, highlighting the significance of drug-target binding affinity in anticipating and mitigating possible adverse effects. In doing so, we aim to contribute to the development of more effective and secure drugs.